Regenxbio Inc (NASDAQ:RGNX) insider Kenneth T. Mills sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, March 20th. The shares were sold at an average price of $29.55, for a total value of $295,500.00. Following the sale, the insider now directly owns 228,530 shares in the company, valued at approximately $6,753,061.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Shares of Regenxbio stock traded down $0.55 during mid-day trading on Thursday, reaching $30.10. The company had a trading volume of 155,864 shares, compared to its average volume of 405,843. Regenxbio Inc has a 12 month low of $16.30 and a 12 month high of $42.00. The company has a market capitalization of $932.80, a P/E ratio of -12.19 and a beta of -1.21.
Regenxbio (NASDAQ:RGNX) last released its quarterly earnings results on Tuesday, March 6th. The biotechnology company reported ($0.51) EPS for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.20. Regenxbio had a negative return on equity of 36.48% and a negative net margin of 704.02%. The company had revenue of $2.04 million during the quarter. equities analysts anticipate that Regenxbio Inc will post -2.44 EPS for the current fiscal year.
A number of equities research analysts recently weighed in on the company. BidaskClub raised Regenxbio from a “hold” rating to a “buy” rating in a research report on Thursday, December 7th. Zacks Investment Research raised Regenxbio from a “hold” rating to a “buy” rating and set a $37.00 price objective on the stock in a research report on Friday, March 16th. Mizuho assumed coverage on Regenxbio in a research report on Monday, February 12th. They set a “neutral” rating and a $28.00 price objective on the stock. Barclays assumed coverage on Regenxbio in a research report on Wednesday, November 22nd. They set an “overweight” rating and a $38.00 price objective on the stock. Finally, TheStreet downgraded Regenxbio from a “c” rating to a “d+” rating in a research report on Tuesday, November 28th. One research analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $40.63.
TRADEMARK VIOLATION NOTICE: “Regenxbio Inc (RGNX) Insider Kenneth T. Mills Sells 10,000 Shares” was reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this news story on another website, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3289992/regenxbio-inc-rgnx-insider-kenneth-t-mills-sells-10000-shares.html.
Regenxbio Company Profile
REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.
Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.